SyntekaBio

At a glance

SyntekaBio filed 116 disclosures in the last 12 months, including 12 insider, 12 5% holder, 3 contract and 1 issuance. The most recent key filing was on Oct 12: A major holder's stake fell from 9.44% to 8.27% (conversion/exercise).

Revenue for 2025 was ₩3.4B, up 2736.7% on 2024. It made an operating loss of ₩10.8B. Debt was 46% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩871.6M and operating loss of ₩5.7B.

The 2025 annual report lists 49 employees with an average tenure of 4.1 years and average pay of ₩61.4M. Its 4 directors and auditors were paid ₩130.4M each on average. It paid no cash dividend for 2025. 정종선 and related parties held 15.10% at year end.

Of 5 recent 5%+ holder reports, 3 raised and 1 cut a stake; the largest stake reported was 17.00% on Jul 29.

From the 2025 annual report

Staff: 49 (39 men, 10 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩3B. Directors and auditors: 4, paid ₩521.6M in total.

No cash dividend was paid for 2025.

Largest shareholder

정종선 holds 13.76%; with 6 related parties the group holds 15.10% of common shares at year end (from 17.18% at the start of the year).

Auditor: 삼정회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

New contracts, last 12 months

2 new supply contracts worth 204% of the revenue stated in the filings.

Amended amounts replace the originals. Subsidiary contracts and terminations are excluded.

Financial summary

5%+ holder reports